Corgenix Medical Corp/Co Sample Contracts

Corgenix Medical Corp/Co – PRESS RELEASE (November 19th, 2014)

DENVER — November 19, 2014 — Corgenix Medical Corporation (OTC QB: CONX.OB) (the “Company”) announced today that it has entered into a memorandum of understanding with plaintiffs’ counsel in the consolidated Nevada putative shareholder class action lawsuit described in the Company’s definitive proxy statement dated October 21, 2014, as supplemented (the “Proxy Statement”), in connection with the Company’s proposed merger with an affiliate of Orgentec Diagnostika (the “Merger”).

Corgenix Medical Corp/Co – CHANGE IN TERMS AGREEMENT (November 7th, 2014)

Extension of Maturity Date. Consistent with our existing periodic payment arrangement, the Maturity Date of the Promissory Note shall be extended to February 5, 2015.

Corgenix Medical Corp/Co – PRESS RELEASE (October 29th, 2014)

DENVER — October 29, 2014 — Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today reported preliminary revenue results for the first quarter (ended September 30, 2014), which came in at approximately $2.2 million versus approximately $2.9 million for the same quarter in the previous year. In addition, due to the lower revenues and the expenses related to the pending strategic merger with Orgentec Diagnostika, the Company incurred a net loss for the period of approximately $770,000 versus net income of approximately $84,000 for the same quarter in the previous year.

Corgenix Medical Corp/Co – September 17, 2014 Dear Corgenix Customer, We are pleased to share with you that Corgenix has signed a merger agreement to be acquired by Orgentec Diagnostika, a leading global provider of specialty diagnostic products. (September 17th, 2014)

This acquisition will greatly expand and enhance the menu of specialty diagnostic tests that we can offer you in the future. You will have access to a broad menu of diagnostic assays across the autoimmune, vascular, infectious disease and organ function specialties. In addition, our increased scale and resources will enable us to invest more in researching and developing the next generation of diagnostic products.

Corgenix Medical Corp/Co – CORGENIX SHORT-TERM INCENTIVE PLAN Fiscal Year 2014 (September 10th, 2014)

This document establishes the Corgenix Short-Term Incentive Plan (“STIP”) for the fiscal year ending June 30, 2014 (“FY 2014”) as approved by the Board of Directors (“Board”) and the Compensation Committee (the “Committee”), and is intended as an administrative reference document for executive management and the Board for the fiscal year. It is to be read in conjunction with the STIP Plan Document; however, the Plan Document will control if any conflict should arise.

Corgenix Medical Corp/Co – CORGENIX SENIOR MANAGEMENT BONUS PLAN Calendar Year 2014 (September 10th, 2014)

This document establishes the Corgenix Senior Management Bonus Plan (“SMBP”) for the calendar year ending December 31, 2014 as approved by the Board of Directors (“Board”) and the Compensation Committee (the “Committee”), and is intended as an administrative reference document for executive management and the Board for the year.

Corgenix Medical Corp/Co – PRESS RELEASE (August 28th, 2014)

· Following the transaction, Corgenix will remain headquartered in Broomfield, Colo., as a subsidiary of Orgentec Diagnostika

Corgenix Medical Corp/Co – AGREEMENT AND PLAN OF MERGER among CORGENIX MEDICAL CORPORATION and CENTENNIAL MEDICAL HOLDINGS, INC. and CENTENNIAL INTEGRATED, INC. Dated August 27, 2014 (August 28th, 2014)

This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated August 27, 2014 by and among and Corgenix Medical Corporation, a Nevada corporation (the “Company”), Centennial Medical Holdings, Inc., a Delaware corporation (“Parent”), and a wholly owned subsidiary of Parent, Centennial Integrated, Inc., a Nevada corporation (“Merger Sub”).

Corgenix Medical Corp/Co – VOTING AGREEMENT (August 28th, 2014)

This VOTING AGREEMENT (this “Agreement”) is entered into as of August 27, 2014 by and among Centennial Medical Holdings, Inc. (“Parent”), and the shareholders of Corgenix Medical Corporation, a Nevada corporation (the “Company”) listed on Schedule A hereto (each, a “Shareholder” and collectively, the “Shareholders”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Merger Agreement (as defined below).

Corgenix Medical Corp/Co – CORGENIX MEDICAL CORPORATION HAS REQUESTED THAT THE PORTIONS OF THIS DOCUMENT DENOTED BY BRACKETS AND ASTERISKS BE ACCORDED CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934. TECHNOLOGY TRANSFER, LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (August 20th, 2014)

This agreement (the “Agreement”) is effective August 15, 2014 by and between Corgenix Medical Corporation a corporation organized and existing under the laws of the State of Nevada and having its principal place of business at 11575 Main Street, Suite 400, Broomfield, Colorado, 80020 (hereinafter referred to as “Corgenix”); and Eli Lilly and Company, a corporation organized and existing under the laws of Indiana and having its principal place of business at Lilly Corporate Center, Indianapolis, IN (hereinafter referred to as “Lilly”). Corgenix and Lilly are also herein referred to as a “Party” or, collectively, the “Parties”.

Corgenix Medical Corp/Co – PRESS RELEASE (August 11th, 2014)

DENVER — August 11, 2014 —Ebola virus outbreaks tend to occur every few years and then go away rapidly. However, this year’s outbreak is the worst in recorded history, with the total number of deaths approaching 1,000. As reported previously, Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, commenced work on a $2.9 million National Institutes of Health (NIH) grant in June.

Corgenix Medical Corp/Co – CORGENIX MEDICAL CORPORATION HAS REQUESTED THAT THE PORTIONS OF THIS DOCUMENT DENOTED BY BRACKETS AND ASTERISKS BE ACCORDED CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934. COLLABORATIVE DEVELOPMENT AND MANUFACTURING AGREEMENT Between HEALTH DIAGNOSTIC LABORATORY, INC. - and - CORGENIX INC. as of October 22, 2013 (October 28th, 2013)

This Collaborative Development and Manufacturing Agreement (this “Agreement”) is made effective as of October 22, 2013 (the “Effective Date”) by and between Health Diagnostic Laboratory, Inc., 737 N 5th Street, Suite 200, Richmond VA 23219 (“HDL”) and Corgenix, Inc., 11575 Main Street, Suite 400, Broomfield CO 80020 (“Corgenix”). HDL and Corgenix are each referred to individually as a “Party” and together as the “Parties”.

Corgenix Medical Corp/Co – PRESS RELEASE (October 28th, 2013)

DENVER — October 28 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would be based on Corgenix’ patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.

Corgenix Medical Corp/Co – PRESS RELEASE (September 10th, 2013)

DENVER — September 10, 2013 — Corgenix Medical Corporation (OTC QB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced signing of a new AtherOx® License and Cooperation Agreement with Eiji Matsuura, Ph.D., an individual of Okayama, Japan. Concurrently with the execution of the new agreement, Dr. Matsuura terminated his arbitration demand of June 28, 2013 related to the April 14, 2010 Amended and Restated License Agreement between the parties.

Corgenix Medical Corp/Co – PROMISSORY NOTE (September 4th, 2013)

PROMISE TO PAY. CORGENIX MEDICAL CORPORATION (“Borrower”) promises to pay to BANK OF THE WEST (“Lender”), or order, in lawful money of the United States of America, the principal amount of One Million Five Hundred Thousand & 00/100 Dollars ($1,500,000.00) or so much as may be outstanding, together with interest on the unpaid outstanding principal balance of each advance. Interest shall be calculated from the date of each advance until repayment of each advance.

Corgenix Medical Corp/Co – BUSINESS LOAN AGREEMENT (September 4th, 2013)

THIS BUSINESS LOAN AGREEMENT dated August 15, 2013, is made and executed between CORGENIX MEDICAL CORPORATION (“Borrower”) and BANK OF THE WEST (“Lender”) on the following terms and conditions. Borrower has received prior commercial loans from Lender or has applied to Lender for a commercial loan or loans or other financial accommodations, including those which may be described on any exhibit or schedule attached to this Agreement. Borrower understands and agrees that: (A) in granting, renewing, or extending any Loan, Lender is relying upon Borrower’s representations, warranties, and agreements as set forth in this Agreement; (B) the granting, renewing, or extending of any Loan by Lender at all times shall be subject to Lender’s sole judgment and discretion; and (C) all such Loans shall be and remain subject to the terms and conditions of this Agreement.

Corgenix Medical Corp/Co – CORGENIX MEDICAL CORPORATION HAS REQUESTED THAT THE PORTIONS OF THIS DOCUMENT DENOTED BY BRACKETS AND ASTERISKS BE ACCORDED CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934. SUPPLY AGREEMENT (September 27th, 2012)

THIS SUPPLY AGREEMENT, together with exhibits attached hereto (“Agreement”) is entered into as of July 1, 2011 (the “Effective Date”) by and between DIADEXUS, INC., organized under the laws of Delaware and having its principal place of business at 343 Oyster Point Boulevard, South San Francisco, California 94080 (“diaDexus”), and CORGENIX, INC., organized under the laws of Delaware and having its principal place of business at 11575 Main Street, Suite 400, Broomfield, CO 80020 (“Corgenix”). diaDexus and Corgenix may each be referred to herein individually as a “Party” or, collectively, as “Parties.”

Corgenix Medical Corp/Co – PRESS RELEASE (June 19th, 2012)

DENVER and SOUTH SAN FRANCISCO— June 19, 2012 — Corgenix Medical Corporation (OTC: CONX.OB) (“Corgenix Medical”), a worldwide developer and marketer of diagnostic test kits, today announced that its wholly owned subsidiary, Corgenix, Inc. (Corgenix, Inc., together with Corgenix Medical, are herein referred to as “Corgenix”), entered into a contract manufacturing and supply agreement with diaDexus, Inc. (OTC: DDXS) (“diaDexus”), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products. Under the terms of the five-year agreement, Corgenix will manufacture and supply the PLAC® Test ELISA product for diaDexus.

Corgenix Medical Corp/Co – FIRST AMENDED AND RESTATED JOINT PRODUCT DEVELOPMENT AGREEMENT (August 2nd, 2011)

This First Amended and Restated Joint Product Development Agreement (“Agreement”) is made and entered into on this 28th day of July, 2011 (“Effective Date”), by and among Corgenix Medical Corporation, a Nevada corporation (“Corgenix”), with its principal place of business at 11575 Main Street, Suite 400, Broomfield, Colorado 80020, Financière Elitech SAS, a société par actions simplifiée organized under the laws of France (“Elitech”), with its principal place of business at 12-12bis, rue Jean Jaurès, 92800 Puteaux, France, and Wescor, Inc., a Utah corporation (“Wescor”), with its principal place of business at 370 West 1700 South, Logan, Utah 84321. Each of Corgenix, Elitech and Wescor are sometimes referred to in this agreement individually as a “Party” and, collectively, as the “Parties.”

Corgenix Medical Corp/Co – REVOLVING PROMISSORY NOTE (July 20th, 2011)

FOR VALUE RECEIVED, the undersigned, CORGENIX MEDICAL CORPORATION, a Nevada corporation (the “Maker”), hereby promises to pay to the order of LSQ FUNDING GROUP, L.C., a Florida limited liability company (“Lender”), at the office of the Lender at 1405 West Colonial Drive, Suite B, Orlando, Florida 32804, or such other place as the holder may designate in writing, the sum of ONE MILLION FIVE HUNDRED THOUSAND AND 00/100 DOLLARS ($1,500,000.00) or such lesser amount as may be outstanding from time to time, together with interest thereon at the rate provided below, such principal sum and interest thereon to be paid as provided herein. All sums due under this Note, whether principal or interest, shall be paid in United States Dollars and immediately available funds on the date and at the place payment is due. All payments shall be applied first to accrued interest and then to principal.

Corgenix Medical Corp/Co – REVOLVING CREDIT AND SECURITY AGREEMENT between CORGENIX MEDICAL CORPORATION “Borrower” and LSQ FUNDING GROUP, L.C. “Lender” Dated: , 2011 (July 20th, 2011)

THIS AGREEMENT (the “Agreement”) is made as of , 2011 by and between Corgenix Medical Corporation, a Nevada corporation (“Borrower”), and LSQ Funding Group, L.C., a Florida limited liability company (“Lender”).

Corgenix Medical Corp/Co – LEASE AMENDMENT NO. 5 (April 15th, 2011)

THIS LEASE AMENDMENT NO. 5 (“Amendment”) is made and entered into as of April 11, 2011, by and between CORGENIX MEDICAL CORPORATION, a Nevada corporation (“Tenant”), and KE DENVER ONE, LLC, a Delaware limited liability company (“Landlord”).

Corgenix Medical Corp/Co – ASSIGNMENT AND ASSUMPTION AGREEMENT (October 12th, 2010)

This Assignment and Assumption Agreement (“Agreement”) is made as of October 1, 2010, by and among Elitech UK Limited, a private limited company organized under the laws of the United Kingdom (“Assignee”), Corgenix Medical Corporation, a Nevada corporation (“Corgenix”), and Corgenix U.K. Ltd., a private limited company organized under the laws of the United Kingdom (“Corgenix U.K.” and, collectively with Corgenix, the “Assignors”).

Corgenix Medical Corp/Co – Contract (October 12th, 2010)

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER SECURITIES LAWS, HAVE BEEN TAKEN FOR INVESTMENT, AND MAY NOT BE SOLD OR TRANSFERRED OR OFFERED FOR SALE OR TRANSFER UNLESS A REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND OTHER APPLICABLE SECURITIES LAWS WITH RESPECT TO SUCH SECURITIES IS THEN IN EFFECT, OR SUCH REGISTRATION UNDER THE SECURITIES ACT AND OTHER APPLICABLE SECURITIES LAWS IS NOT REQUIRED.

Corgenix Medical Corp/Co – AMENDMENT TO THE BYLAWS OF CORGENIX MEDICAL CORPORATION (October 5th, 2010)
Corgenix Medical Corp/Co – PROMISSORY NOTE (September 1st, 2010)

FOR VALUE RECEIVED, the undersigned, Corgenix Medical Corporation (“Maker”) hereby promises to pay to the order of Medical & Biological Laboratories, Co., Ltd., with a principal place of business at 510 Marunouchi 3 Chome, Naka-ku, Nagoya 460-0002 Japan (“Holder”), the sum of ONE HUNDRED TWENTY FIVE THOUSAND DOLLARS ($ 125,000.00), together with interest on the unpaid principal amount from time to time outstanding at the rates hereinafter provided until paid in full; provided that all outstanding amounts due under this note shall be payable no later than August 1, 2012. The principal amount of this note shall be payable in monthly installments and interest on the unpaid principal balance shall be due and payable together with each payment of principal, all as hereinafter set forth. The proceeds of this note are to be used to repurchase 220,071 shares of Maker’s common stock currently held by Holder.

Corgenix Medical Corp/Co – SECOND AMENDMENT TO COMMON STOCK PURCHASE AGREEMENT AND WARRANT (September 1st, 2010)

Corgenix Medical Corporation, a Nevada corporation (the “Company”), and Medical & Biological Laboratories Co., Ltd., a corporation organized under the laws of Japan (the “Purchaser”), hereby amend certain provisions of the Common Stock Purchase Agreement dated as of July 1, 2002 and the Common Stock Purchase Warrant dated as of July 3, 2002, each by and between the Company and the Purchaser (the “Purchase Agreement”), as of the 15th day of July, 2008 (this “Second Amendment”).

Corgenix Medical Corp/Co – THIRD AMENDMENT TO COMMON STOCK PURCHASE AGREEMENT AND WARRANT (September 1st, 2010)

Corgenix Medical Corporation, a Nevada corporation (the “Company”), and Medical & Biological Laboratories Co., Ltd., a corporation organized under the laws of Japan (the “Purchaser”), hereby amend, as of the first day of August, 2010 (this “Third Amendment”), certain provisions of the Common Stock Purchase Agreement dated as of July 1, 2002 and the Common Stock Purchase Warrant dated as of July 3, 2002, each by and between the Company and the Purchaser (the “Purchase Agreement”).

Corgenix Medical Corp/Co – Contract (July 16th, 2010)

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER SECURITIES LAWS, HAVE BEEN TAKEN FOR INVESTMENT, AND MAY NOT BE SOLD OR TRANSFERRED OR OFFERED FOR SALE OR TRANSFER UNLESS A REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND OTHER APPLICABLE SECURITIES LAWS WITH RESPECT TO SUCH SECURITIES IS THEN IN EFFECT, OR SUCH REGISTRATION UNDER THE SECURITIES ACT AND OTHER APPLICABLE SECURITIES LAWS IS NOT REQUIRED.

Corgenix Medical Corp/Co – MUTUAL CONFIDENTIALITY AGREEMENT (July 16th, 2010)

This Mutual Confidentiality Agreement (this “Agreement”), dated as of July 16, 2010, is entered into by and among Financière Elitech SAS, a société par actions simplifiée organized under the laws of France (“Elitech”), Wescor, Inc., a Utah corporation (“Wescor”), Elitech UK Limited, a private limited company organized under the laws of the United Kingdom (“Elitech UK” and, collectively with Elitech and Wescor, the “Elitech Group”), Corgenix Medical Corporation, a Nevada corporation (“Corgenix”), and Corgenix U.K. Ltd., a private limited company organized under the laws of the United Kingdom (“Corgenix U.K.” and, collectively with Corgenix, the “Corgenix Group”).

Corgenix Medical Corp/Co – MASTER DISTRIBUTION AGREEMENT (July 16th, 2010)

This Master Distribution Agreement (“Agreement”) is made and entered into on this 16th day of July, 2010 (“Effective Date”), by and between Corgenix Medical Corporation, a Nevada corporation (“Corgenix”), with its principal place of business at 11575 Main Street, Suite 400, Broomfield, Colorado 80020, United States of America, and Elitech UK Limited, a private limited company formed under the laws of the United Kingdom (“Distributor”), with its principal place of business at Unit 6 River Park Industrial Estate, Billet Lane, Berkhamsted, Herts HP4 IHL, England. Corgenix and Distributor are sometimes referred to in this Agreement individually as a “Party” and, collectively, as the “Parties.”

Corgenix Medical Corp/Co – ASSIGNMENT AND ASSUMPTION AGREEMENT (July 16th, 2010)

This Assignment and Assumption Agreement (“Agreement”) is made as of , 2010, by and among Elitech UK Limited, a private limited company organized under the laws of the United Kingdom (“Assignee”), Corgenix Medical Corporation, a Nevada corporation (“Corgenix”), and Corgenix U.K. Ltd., a private limited company organized under the laws of the United Kingdom (“Corgenix U.K.” and, collectively with Corgenix, the “Assignors”).

Corgenix Medical Corp/Co – COMMON STOCK PURCHASE AGREEMENT by and among CORGENIX MEDICAL CORPORATION FINANCIÈRE ELITECH SAS AND WESCOR, INC. July 12, 2010 (July 16th, 2010)

THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into effective as of July 12, 2010 (the “Effective Date”), by and among Corgenix Medical Corporation, a Nevada corporation (the “Company”), Financière Elitech SAS, a société par actions simplifiée organized under the laws of France (“Elitech”), and Wescor, Inc., a Utah corporation and subsidiary of Elitech (“Investor”).

Corgenix Medical Corp/Co – JOINT PRODUCT DEVELOPMENT AGREEMENT (July 16th, 2010)

This Joint Product Development Agreement (“Agreement”) is made and entered into on this 16th day of July, 2010 (“Effective Date”), by and between Corgenix Medical Corporation, a Nevada corporation (“Corgenix”), with its principal place of business at 11575 Main Street, Suite 400, Broomfield, Colorado 80020, and Financière Elitech SAS, a société par actions simplifiée organized under the laws of France (“Elitech”), with its principal place of business at 12-12bis, rue Jean Jaurès, 92800 Puteaux, France. Corgenix and Elitech are sometimes referred to in this agreement individually as a “Party” and, collectively, as the “Parties.”

Corgenix Medical Corp/Co – AMENDMENT TO THE BYLAWS OF CORGENIX MEDICAL CORPORATION (July 16th, 2010)

INAPPLICABILITY OF ACQUISITION OF CONTROLLING INTEREST STATUTES. Notwithstanding any other provision in these Bylaws to the contrary, and in accordance with the provisions of Section 78.378 of the Nevada Revised Statutes (“NRS”), the provisions of NRS §§ 78.378 to 78.3793, inclusive (or any successor statutes thereto), relating to acquisitions of controlling interests in the corporation do not apply to any and all acquisitions of shares of the corporation’s common stock, par value $.001 per share, effected by Financière Elitech SAS, a corporation organized under the laws of France, WESCOR, INC., a Utah corporation, or any of their respective affiliates.